Exhaled Nitric Oxide Changes During Acclimatization to High Altitude: A Descriptive Study by Summerfield, DT et al.
This is a repository copy of Exhaled Nitric Oxide Changes During Acclimatization to High 
Altitude: A Descriptive Study.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/138033/
Version: Accepted Version
Article:
Summerfield, DT, Coffman, KE, Taylor, BJ orcid.org/0000-0001-5229-941X et al. (2 more 
authors) (2018) Exhaled Nitric Oxide Changes During Acclimatization to High Altitude: A 
Descriptive Study. High Altitude Medicine and Biology, 19 (3). pp. 215-220. ISSN 
1527-0297 
https://doi.org/10.1089/ham.2017.0109
(c) Mary Ann Liebert, Inc. This is an author produced version of a paper published in High 
Altitude Medicine and Biology. Uploaded in accordance with the publisher's self-archiving 
policy. 
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
Summerfield 
Exhaled nitric oxide changes during acclimatization to high altitude: A descriptive study.  
Douglas T. Summerfield*, Kirsten E. Coffman, Bryan J. Taylor, Amine N. Issa, Bruce D. 
Johnson 
Corresponding Author 
Douglas T. Summerfield*:  Critical Care and Aerospace Medicine, Mayo Clinic, 200 1st St SW, 
Rochester, MN, USA, 55905.  Tel +1 (507) 226-7383.  Fax: +1 (641)428-7866 Email: 
Douglas.Summerfield@mercyhealth.com 
Authors: 
Kirsten E. Coffman: Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 1st 
St SW, Rochester, MN, USA, 55905. Tel +1 (507) 255-1557, Fax: +1 (507) 255-9938, Email: 
kirsten.e.coffman@gmail.com     
 
Bryan J. Taylor: School of Biomedical Sciences, University of Leeds, Garstang 5.68, Leeds, UK, 
LS2 9JT.  Tel +44(113) 343-0482, Email b.j.taylor@leeds.ac.uk 
Amine N. Issa: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo 
Clinic, 200 1st St SW, Rochester, MN, USA, 55905. Tel +1 (507) 293-0188 Fax: +1 (507) 255-
9938, Email: Issa.Amine@mayo.edu. 
Bruce D. Johnson: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo 
Clinic, 200 1st St SW, Rochester, MN, USA, 55905.  Tel +1 (507) 284-4375,  Fax: +1 (507) 255-
9938,  Email: Johnson.Bruce@mayo.edu. 
 
 
 
 
Short Title:  PeNO changes during acclimatization  
2 
Summerfield 
ABSTRACT 
Aims: This study describes differences in the partial pressures of exhaled nitric oxide (PeNO) 
between subjects fully acclimatized to 5,300 m and those who have just arrived to high altitude.  
Methods:  PeNO was determined in eight subjects newly exposed and non-acclimatized (Non-ACC) 
to high altitude and compared to nine subjects who had acclimatized (ACC) to high altitude for one 
month.  Additionally, systolic pulmonary artery pressure (sPAP) and arterial oxygen saturation 
(SaO2) were measured in all participants.  These measurements were repeated in the Non-ACC group 
5 and 9 days later. 
Results:  PeNO levels on day 1 were significantly higher in the Non-ACC vs. ACC cohort (8.7 ± 
3.5 vs. 3.9 ± 2.2 nmHg, p = 0.004).  As the Non-ACC group remained at altitude, PeNO levels 
fell and were not different when compared to the ACC group by day 9 (5.9 ± 2.4 vs. 3.9 ± 2.2 
nmHg, p = 0.095). Higher sPAP was correlated with lower PeNO levels in all participants (R = -
0.50, p = 0.043).  PeNO levels were not correlated with SaO2.   
Conclusion:  As individuals acclimatized to high-altitude PeNO levels decreased.  Even after 
acclimatization, PeNO levels continued to play a role in pulmonary vascular tone. 
 
Keywords:  exhaled nitric oxide, high altitude populations, acclimatization, systolic pulmonary 
artery pressure   
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INTRODUCTION 
In the respiratory system, endogenously produced nitric oxide (NO) plays a major role in the 
regulation of bronchiolar and pulmonary vascular tone, with NO dysregulation seen in many 
disease states (Barnes and Belvisi, 1993; Gaston et al., 1994; Ricciardolo, 2003).   During states 
of inflammation such as asthma, NO levels, as measured by exhaled nitric oxide (eNO), have 
been shown to increase (Kharitonov et al., 1994; Persson et al., 1994).  Conversely, low levels of 
eNO have been observed in patients with pulmonary hypertension, and in subjects who are prone 
to high altitude pulmonary edema (HAPE) during acute (within 22 hours) exposure to hypobaric 
hypoxia (Beall et al., 2012; Duplain et al., 2000).   Additional evidence for the importance of 
endogenously produced NO within the airways is seen by the use of exogenous NO as a 
therapeutic agent.  In physiologic states with low NO conditions or where pulmonary 
vasodilation is required, such as acute cor pulmonale from a massive pulmonary embolism 
(Summerfield et al., 2012) or high altitude pulmonary edema (HAPE) (Scherrer et al., 1996), the 
administration of exogenous NO can be therapeutic.  Regardless, both exogenously administered 
as well as endogenously produced NO are rapidly inactivated within the pulmonary vasculature 
through nitrosylation during binding to hemoglobin.  In this way, the effects of NO are thought 
to be relatively pulmonary selective (Rimar and Gillis, 1993).  
Pulmonary vasculature production of NO is catalyzed by nitric oxide synthases, both endothelial 
eNOS and inducible iNOS.  These enzymes oxidize L-arginine to NO and L-citrulline. 
Mechanistically, NO induces soluble cyclic guanosine monophosphate (cGMP) which in turn 
decreases intracellular calcium concentrations.  Additionally, release of intracellular calcium 
from the sarcoplasmic reticulum is inhibited and the sensitivity of myosin to calcium is reduced.  
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In smooth muscle these overall changes lead to smooth muscle relaxation and pulmonary 
vasodilation (Murad, 1986; Palmer et al., 1988). 
Prior groups have found that HAPE-susceptible subjects who sojourn to high-altitude show 
lower eNO levels and higher systolic pulmonary artery pressures (sPAP) as compared to controls 
(Duplain et al., 2000). Furthermore, higher sPAP and lower eNO was associated with the 
formation of pulmonary edema in a subset of HAPE-susceptible subjects, potentially suggesting 
increased hypoxic pulmonary vasoconstriction in these individuals (Duplain et al., 2000). The 
reduced level of eNO seen in HAPE-prone individuals is the basis for treatment of HAPE with 
inhaled NO (iNO), which has been shown to improve decreased oxygen saturation associated 
with HAPE (Scherrer et al., 1996).  Interestingly, the administration of exogenous iNO decreased 
pulmonary artery pressures and increased arterial oxygen saturations only in HAPE-prone 
individuals exposed to hypobaric hypoxia.  In non-HAPE prone subjects it actually worsened 
oxygenation (Scherrer et al., 1996). 
Although changes in sPAP and eNO have been well described with ascent to high altitude, they 
have not been monitored as subjects acclimatize.  Thus, it is not known what, if any, further 
changes occur during adaptation to high altitude.   Our aim was to investigate associations 
between eNO, sPAP, Hemoglobin, and SaO2 during acclimatization to hypobaric hypoxia. 
METHODS 
Subjects 
Seventeen healthy non-smoking adult lowlanders (2 female) with no history of cardiorespiratory 
or metabolic disease participated in the study. Each participant gave written informed consent 
after being provided a detailed description of the study requirements. The experimental 
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procedures were approved by the Mayo Clinic Institutional Review Board and were performed in 
accordance with the ethical standards of the Declaration of Helsinki. All study participants were 
prohibited from prophylactic administration of any medication to aid altitude acclimatization 
(e.g., sildenafil, acetazolamide). Moreover, no subject required emergent pharmaceutical 
treatment (e.g., dexamethasone) for high altitude illness. 
Expedition details and experimental procedures 
All experimental procedures were performed at Mount Everest base camp (5,300 m). To reach base 
camp, each participant travelled to Kathmandu, Nepal (1,400m) before being transported by airplane 
to Lukla, Nepal (2,860 m). From Lukla, the participants completed an 8- to 10-day hike at 
progressively increasing altitudes to reach base camp. The 17 participants were separated into two 
groups: Group 1 (n = 9, 2 femaleDFFOLPDWL]HGµ$&&¶) arrived and stayed at base camp for ~1 
month before the arrival of Group 2 (n = 8, 0 female; non-DFFOLPDWL]HGµ1RQ-$&&¶). Within 24 h of 
arrival of the Non-ACC group to base camp, exhaled nitric oxide (eNO), systolic pulmonary artery 
pressure (sPAP), arterial oxygen saturation (SaO2) (Nonin Medical Inc, Plymouth, Minnesota), and 
hemoglobin (Hgb) (Abbott iSTAT, Princeton, NJ) were measured. In addition, eNO and sPAP were 
measured on day 5 and day 9 at base camp in Non-ACC. 
Exhaled nitric oxide 
Exhaled nitric oxide (eNO) was measured in triplicate in parts per billion using a hand-held 
electrochemical detector (NIOX MINO Aerocrine, New Providence, NJ) according to standard 
procedures (Silkoff, 2005). Briefly, subjects inhaled NO free air to total lung capacity (TLC) before 
exhaling for ~10 s against a counter pressure of 5-20 cmH2O. By allowing closure of the soft palate, 
this technique isolates the small airways and prevents the measurement of NO from the nasal cavity 
(Pietropaoli et al., 1999; Silkoff et al., 1997, 1998).  At the time of the study, all subjects were non-
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smokers. In addition, each participant abstained from eating nitrogen enriched foods for at least 3 h 
before each measure of eNO. 
When reporting eNO at altitude, it is necessary to convert eNO (ppb) to partial pressure of eNO 
(PeNO, nmHg) at normal temperature and pressure conditions so that eNO values can be 
accurately compared across studies and altitudes. Therefore, the correction factor determined by 
Hemmingsson et al (Hemmingsson et al., 2009) for the NIOX MINO at an altitude of 5,000 m 
was applied, followed by conversion from ppb to nmHg, as follows: 
ܱܲ݁ܰሺ݊݉ܪ݃ሻ ൌ ቆܱ݁ܰሺ݌݌ܾሻ ?Ǥ ? ? ? כ  ? ? ?݉ ݉ܪ݃ቇ כ  ?ݔ ? ?ିଷ 
For ease of comparability with other reported data, it should be noted that 1 nm Hg= 1.333 mbar. 
Systolic pulmonary artery pressure 
Systolic pulmonary artery pressure (sPAP) was estimated from the peak velocity of tricuspid 
regurgitation (TRVMAX) using a modified Bernoulli equation as described previously (Yock and Popp, 
1984). With participants in the left lateral supine position, the TR jet was located using 2D-color 
Doppler echocardiography in the four chamber view. To determine TRVMAX, the continuous wave 
sampler was positioned within and parallel to the regurgitation jet and sPAP was computed as 4 × 
TRVMAX + right atrial pressure (RAP). RAP was estimated from the ratio between minimum inferior 
vena cava (IVC) diameter during a maximal sniff maneuver and maximum IVC diameter during 
normal respiration (Lawrence G Rudski MD et al., 2010). TRVMAX and IVC dimensions were 
measured in triplicate in each participant at each time point.  
Statistical analyses 
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Independent samples t-test was used to compare absolute measures of PeNO, sPAP, and SaO2 between 
ACC vs. Non-ACC on day 1 at base camp. One-way repeated measures ANOVA was used to compare 
absolute measures of PeNO and sPAP across time (base camp day 1 vs. day 5 vs. day 9) in the Non-
ACC group. Following significant main effects, planned pairwise comparisons were made using the 
%RQIHUURQLPHWKRG,QDGGLWLRQ3HDUVRQ¶VSURGXFW-moment correlation coefficient (r) was computed 
to assess the relationships between PeNO and either sPAP, SaO2, or Hgb. The acceptable type I error 
was set at P <  0.05. Data are expressed as group means ± SD. Statistical analyses were performed 
using SPSS version 22.0 for Windows (IBM, Armonk, NY). 
RESULTS 
Effect of high-altitude on PeNO, sPAP, and SaO2 
Upon arrival at base camp, group mean PeNO was greater in the Non-ACC vs. the ACC group (Figure 
1; Table 1). Conversely, neither sPAP nor SaO2 was different between the Non-ACC and ACC group 
(Table 1). In the Non-ACC group, PeNO was not different on day 5 but significantly lower on day 9 
vs. day 1 at base camp (Table 1). Indeed, after 9 days at base camp, PeNO was not different in the 
Non-ACC group compared to the ACC group 9 days prior (5.9 ± 2.4 vs. 3.9 ± 2.2 ppb, p = 0.095). 
 
Associations between PeNO, sPAP, SaO2, and Hgb 
Previous studies have also found a correlation between sPAP and PeNO levels. Figure 2 shows 
this relationship for all subjects combined. Indeed, higher PeNO levels were significantly 
correlated with lower sPAP (Figure 2; R = -0.50, p = 0.043). 
PeNO levels were also compared to resting daytime SaO2 for both groups (Figure 3).  There 
were no correlations between PeNO levels and daytime SaO2, in either the Non-ACC nor ACC 
group, nor combined. However, individual performances were also recorded. Interestingly, it was 
8 
Summerfield 
noted that the team member in the ACC group with the highest PeNO level and highest 
corresponding SaO2 was able to subsequently summit to a height of 8,848 m without oxygen.  
Conversely, the member in the ACC group who had the lowest PeNO and the corresponding 
lowest SaO2 was unable to successfully complete the climb. 
Finally, Hgb levels were measured in all Non-ACC subjects and a subset of ACC subjects on 
Day 1 only. While not significant, there was a trend toward a lower PeNO being associated with 
a higher Hgb level (Figure 4; R = -0.56, p = 0.056).    
DISCUSSION 
Our results show that PeNO levels in subjects who have acclimatized to 5,300 m are significantly 
lower than those who have just arrived to that altitude.  Additionally, the newly arrived group 
showed a significant decrease in PeNO levels after 9 days at high-altitude, approaching levels 
seen in the ACC group.  Our data is also consistent with prior work done by Duplain and 
colleagues that showed an inverse relationship between sPAP and PeNO when subjects are 
exposed to high altitude (Duplain et al., 2000).  Furthermore, there was no correlation between 
PeNO and daytime oxygen saturations in either group nor combined.  Overall this data 
demonstrates a fall in PeNO levels during the acclimatization process, but would suggest that 
PeNO is still important for continued regulation of pulmonary vascular tone. 
There was also a trend toward a lower PeNO level being associated with a higher Hgb level.  
This trend could be explained by the fact that NO is rapidly inactivated within the pulmonary 
vasculature through nitrosylation during binding to hemoglobin.  Thus increased hemoglobin 
may hasten the inactivation of NO.  
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Previous studies have evaluated the role of pulmonary NO during acclimatization; however, 
these studies looked at changes across different altitudes as well as different subjects' ethnicity.  
Wu et al. examined both Tibetan and non-Tibetan infants born at 3,658 m and compared them to 
non-Tibetan infants born at 16 m.  They found infants born at high altitude had increased levels 
of PeNO during their first week of life when compared to those born near sea level.  Genetic 
differences were detected as well.  Non-Tibetan infants born at altitude were more likely to 
require oxygen supplementation to improve their saturations, suggesting a genetic adaptation in 
those groups who permanently reside at altitude (Wu et al., 2016).  In contrast to Tibetan 
adaptation, differences in adaptation of Andean adults may not be dependent on NO 
concentrations thus suggesting genetic differences in adaptation.  This was demonstrated by 
Schwab et al.  Their research, performed in Bolivia, compared PeNO and sPAP of native 
Bolivians to sex-matched Caucasians exposed to 3600 m.  They found no differences between 
the two groups when PeNO and sPAP were compared (Schwab et al., 2008).  Gender differences 
in eNO levels may also exist, as Li et al. found average fractional eNO (ppb) levels to be higher 
in male vs. female Tibetans  (Li, 2014). Additionally,  Li also found eNO levels were inversely 
related to altitude, with higher altitude subjects demonstrating lower eNO levels (Li, 2014).   
Other research, including ours, also demonstrated  that PeNO levels decrease during exposure to 
altitude (Brown et al., 2006; Donnelly et al., 2011; Duplain et al., 2000).  However, one must be 
careful in the reporting of eNO levels taken at altitude.  In 2009, Hemmingsson and colleagues 
argued that altitude studies implementing the use of the NIOX MINO device may have errors 
and results should be reported as partial pressures rather than the fractional volume (parts per 
billion and typically termed exhaled or eNO levels) that the device detects.  Their  reasons for 
this recommendation are as follows: mass flow decreases with altitude, eNO fractional 
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concentrations increase with decreasing mass flow, reduced ambient pressure leads to a 
proportionally lower pressure of NO, and finally that the electrochemical detector is more 
sensitive to NO at altitude.  Thus, the displayed values would not reflect the true decrease in 
eNO at altitude (Hemmingsson et al., 2009).   
Importantly, HemmingssRQ¶VSDSHUGHWDLOVDFRQYHUVLRQZKLFKFDQEHXVHGIRUH12LQUHSRUWLQJ
partial pressures at altitude (Hemmingsson et al., 2009).    This conversion was applied to our 
subjects. Of note, the conversion factor depends on the study of a specific NIOX MINO device, 
and thus it is possible that the conversion factor may be different on the device used presently. 
This incorporates another limitation in that we were unable to calibrate the NIOX MINO at 
altitude.  Thus, although the values were converted from ppb to nmHg, the values were not able 
to be verified while at altitude.  Importantly, however, the measurements between the two 
cohorts were taken at the same altitude and at the same time.  Thus, the differences seen between 
the two cohorts are comparable, even if the absolute values are not. All in all, consistency in 
reporting high altitude eNO measurements is crucial to the ability to compare across altitudes 
and studies.  
The mechanism for changes in PeNO at altitude and the subsequent development of high altitude 
SXOPRQDU\HGHPDLQVRPHLQGLYLGXDOVFRQWLQXHVWREHLQYHVWLJDWHG'XSODLQ¶VZRUNVXJJHVWHG
that decreased eNO in HAPE-prone subjects may be due to a defect in pulmonary epithelial NO 
synthesis which may lead to increased hypoxic pulmonary vasoconstriction and subsequent 
pulmonary edema (Duplain et al., 2000).  Pulmonary blood flow appears to have an effect on 
both eNO as well as plasma concentrations themselves.  This was demonstrated by Tworetzky 
who measured eNO and plasma NO levels before and after atrial septal defects were repaired.  
After closure of the defect, both levels eNO and plasma levels fell within 30 minutes.  This 
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occurred without corresponding changes in either average pulmonary or systemic artery 
pressures (Tworetzky et al., 2000). 
During our study, PeNO levels in the ACC group were lower; this may be due in part to the 
length of stay at altitude leading to an increased elimination of NO, which was also proposed by 
Hemmingsson (Hemmingsson et al., 2009).  It has also been speculated that lower bioavailability 
of its precursors would also lead to lower eNO levels.   This was hypothesized by Schneider and 
colleagues.  Since NO is produced during the conversion of arginine to L-citrulline they showed 
that after exposure to an altitude of 4,350 m L-citruline levels were decreased.  L-citruline levels 
as well as SaO2 levels increased with an infusion of arginine into subjects.   In addition those 
subjects with symptoms of acute mountain sickness (AMS) demonstrated a slight decrease in 
AMS scores once L-arginine had been administered (Schneider et al., 2001).  Further evidence to 
support this was described by Lundberg and colleagues who found that the inorganic anions 
nitrate (NO3-) and nitrites (NO2-), which were previously believed to be inert end products, can 
be recycled in vivo during hypoxic states and form an alternate pathway for NO production 
(Lundberg et al., 2008). 
In this unblinded study, physical performance of each subject could also be observed.  The most 
striking observation made was within the ACC group, between the subject with the highest 
PeNO level and the one with the lowest.   The former also maintained the highest resting oxygen 
saturation with the latter achieving the lowest resting oxygen saturation.  Furthermore, the latter 
was unable to summit to 8,848 m even on supplemental oxygen, while the former who 
maintained a higher PeNO level was able to summit without oxygen.  This may be partially 
explained by work done in 2000 by Tsuchiya et al.  They found that exhaled NO concentrations 
in lung healthy volunteers were positively correlated with PaO2 and negatively correlated with 
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the alveolar-arterial (A-a) oxygen gradient.(Tsuchiya et al., 2000). Larger A-a gradients would 
be expected to be seen in subjects with underlying diffusion problems. 
Previously, MacInnis et al. has shown a correlation between altitude sickness and low baseline 
FENO levels (MacInnis et al., 2012).  However, future research should seek to validate and use 
PeNO levels as a performance predictor for those traveling to high altitude, either prior to travel 
or during the journey itself.  Conceivably an individual attempting to operate at high altitude and 
who might be at risk for performance degradation or the development of HAPE could be 
identified with falling PeNO levels before they were affected.  Mitigation strategies for these 
individuals, such as the use of supplemental oxygen earlier or removal from the exposure 
through descent, could also be implemented.  Additionally, in the future it may be possible to 
preselect individuals who are well suited for high altitude exposure.  This would benefit those 
interested in high altitude experiences in an elective nature such as a sport climber, as well as 
those required to function at high altitude such as some military personnel operating in these 
environments. 
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